ES2127190T3 - Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo). - Google Patents

Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo).

Info

Publication number
ES2127190T3
ES2127190T3 ES91115080T ES91115080T ES2127190T3 ES 2127190 T3 ES2127190 T3 ES 2127190T3 ES 91115080 T ES91115080 T ES 91115080T ES 91115080 T ES91115080 T ES 91115080T ES 2127190 T3 ES2127190 T3 ES 2127190T3
Authority
ES
Spain
Prior art keywords
chicken
cnp
biologically active
active peptide
new biologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91115080T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2127190T3 publication Critical patent/ES2127190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN NUEVO PEPTIDO QUE PRESENTA UNA ACCION NATRIURETICA Y UNA ACTIVIDAD VASODEPRESORA, Y POR TANTO, SE PUEDE APLICAR COMO REACTIVO DE DIAGNOSTICO. EL NUEVO PEPTIDO SE PRODUCE MEDIANTE EL PROCEDIMIENTO DE ENERGIA GENETICA ASI COMO MEDIANTE METODOS DE PURIFICACION DE LOS SESOS DE POLLOS O MEDIANTE SINTESIS QUIMICAS.
ES91115080T 1990-09-07 1991-09-06 Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo). Expired - Lifetime ES2127190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238293A JP2977158B2 (ja) 1990-09-07 1990-09-07 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）

Publications (1)

Publication Number Publication Date
ES2127190T3 true ES2127190T3 (es) 1999-04-16

Family

ID=17028039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91115080T Expired - Lifetime ES2127190T3 (es) 1990-09-07 1991-09-06 Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo).

Country Status (8)

Country Link
US (1) US5338830A (es)
EP (1) EP0475291B1 (es)
JP (1) JP2977158B2 (es)
AT (1) ATE175210T1 (es)
DE (1) DE69130696T2 (es)
DK (1) DK0475291T3 (es)
ES (1) ES2127190T3 (es)
GR (1) GR3029628T3 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
JP7253220B2 (ja) * 2015-07-31 2023-04-06 株式会社 イギス Ｃｎｐ環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
GR3029628T3 (en) 1999-06-30
ATE175210T1 (de) 1999-01-15
DE69130696D1 (de) 1999-02-11
DK0475291T3 (da) 1999-08-30
JP2977158B2 (ja) 1999-11-10
EP0475291B1 (en) 1998-12-30
EP0475291A1 (en) 1992-03-18
JPH04120094A (ja) 1992-04-21
US5338830A (en) 1994-08-16
DE69130696T2 (de) 1999-06-10

Similar Documents

Publication Publication Date Title
ES2127190T3 (es) Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo).
ES2127189T3 (es) Peptido nuevo biologicamente activo procedente de una rana (rana-cpn).
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
EP0711173A4 (en) INSULATED PEPTIDES THAT MAKE 10 COMPLEXES WITH MHC MULEKÜL HLA-C-KLON AND THEIR USE
DE69306956D1 (de) Katalytische verbrennung von organischen verbindungen
IT1229190B (it) Aumentato recupero di petrolio mediante iniezione ciclica di prodotti chimici fluorurati.
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
ATE30010T1 (de) Verfahren zur herstellung von ethylen-ethangemischen.
ES2063834T3 (es) Tgf-beta 1/beta 2: un nuevo factor del crecimiento-beta transformante quimerico.
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
DE69406214D1 (de) Verfahren zur Reinigung von für den menschlichen Verbrauch bestimmtem Wasser
DE69534470D1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
FR2657791B1 (fr) Compose chimique contenant des alcalins ou des alcalino-terreux catalyseur en contenant et procede de solvolyse utilisant ledit catalyseur.
ATE14126T1 (de) Verfahren zur herstellung von 2-acyl1,3,4,6,7,11b-2h-hexahydro-4-pyrazino(2,1a)isochinolinonen und zwischenprodukte.
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
DE59301131D1 (de) Metalle und/oder Oxide enthaltende Katalysatorelemente und Verfahren zum oxidativen Abbau von cyclischen organischen Verbindungen
ATE64370T1 (de) Herstellung von diamino- und dialkylaminobenzoldiolen.
RO95059A (ro) Procedeu pentru prepararea unor cicloalcancarboxanilide
ES2039312T3 (es) Peptido bacteriocina.
DK0661328T3 (da) Hidtil ukendte epoxid-amin-addukter som hærdere til vandige epoxidsystemer
ES2059766T3 (es) Precursor de prostaglandinas y su produccion.
JPS5411323A (en) Production of linear polyurethane elestomers
GR3017585T3 (en) Process for the removal of olefinic impurities from partially halogenated fluorochlorocarbons.
ATE92077T1 (de) Enzymhemmer und methode zu dessen herstellung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475291

Country of ref document: ES